Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 1072 clinical trials
A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (SubQSA)  

The primary purpose of this study is to assess the efficacy (overall response rate) of subcutaneous (SC) via on body delivery system (SC-OBDS) isatuximab in combination with weekly carfilzomib and dexamethasone (Kd) in adult participants with RRMM having received 1 to 3 prior lines of therapy.

  • 0 views
  • 19 May, 2026
  • 1 location
A Multicentre Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment

This study is to see if the standard of care subcutaneous injection of bortezomib can safely be administered at home by the patient or caregiver. All tests and assessments are based on standard of care procedures.

cancer
bortezomib
multiple myeloma
  • 0 views
  • 24 Nov, 2025
  • 1 location
Managing Pain and Symptom Burden Caused by Chemotherapy in People With Myeloma or Lymphoma

The purpose of this study is to find out whether acupuncture treatments can reduce the need for opioid medication when managing pain caused by chemotherapy. The study will compare the effects of adding acupuncture to usual pain management with those of usual pain management alone, in reducing opioid use by …

pain management
high dose chemotherapy
lymphoma
stem cell transplantation
multiple myeloma
  • 0 views
  • 19 Feb, 2024
  • 2 locations
First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL

Primary Objective: To determine the maximum tolerated dose (MTD) of SAR442257 administered as a single agent in patients with relapsed and refractory multiple myeloma (RRMM) and refractory non-Hodgkin lymphoma (RR-NHL), and determine the recommended Phase 2 dose (RP2D) Secondary Objectives: To characterize the safety profile of SAR442257 To characterize the …

measurable disease
ct scan
neuropathy
recurrent disease
hodgkin's disease
  • 0 views
  • 19 Feb, 2024
  • 5 locations
Longitudinal Data Registry of Plasma Cell Dyscrasia  

This study aims to identify clinical characteristics, response and clinical outcome of plasma cell dyscrasia (PCD) diagnosed in Zhongshan Hospital, Fudan University from May 2023. In its current version, the registry incorporates historical data (collected from 2007) and is prospectively collecting follow-up data and recording patient outcomes.

  • 0 views
  • 10 Jan, 2025
  • 2 locations
COVID-19 Infection and Multiple Myeloma

Collect in an observational study the outcomes of COVID19 infection in MM patients across Europe.

covid-19
multiple myeloma
  • 0 views
  • 19 Feb, 2024
  • 8 locations
Multiple Myeloma and Environmental Exposure to Pesticides in the French West Indies: A Population Based Case-control Study.

Multiple myeloma (MM) is a malignancy of plasma cells engaging in monoclonal immunoglobulin production. A strong presumption was established between exposure to pesticides and the risk of MM.

monoclonal antibodies
multiple myeloma
cancer
monoclonal protein
immunoglobulins
  • 0 views
  • 19 Feb, 2024
  • 2 locations
A Prospective Non-interventional Multinational Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM)

Primary Objective: To assess the effectiveness, in terms of overall response rate (ORR) of isatuximab patients with RRMM in routine clinical practice, within 12 months To assess other effectiveness parameters such as progression free survival (PFS), PFS rate (PFSR), duration of response (DoR), time to response, time and intent to …

line of therapy
isatuximab
multiple myeloma
carcinoma
complete resection
  • 0 views
  • 19 Feb, 2024
  • 4 locations
A Prospective Non-interventional Multinational Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM)

Primary Objective: To assess the effectiveness, in terms of overall response rate (ORR) of isatuximab patients with RRMM in routine clinical practice, within 12 months To assess other effectiveness parameters such as progression free survival (PFS), PFS rate (PFSR), duration of response (DoR), time to response, time and intent to …

isatuximab
multiple myeloma
carcinoma
complete resection
refractory multiple myeloma
  • 0 views
  • 19 Feb, 2024
  • 11 locations
Bone Pain in Multiple Myeloma- a Translational Study

Secondary research questions: Are the alterations in the bone innervation of myeloma patients similar to those of immunocompetent animal models of the disease (the 5TGM1 model)? Is serum paraprotein correlated with the subjective experience of myeloma-induced bone pain?

bone pain
multiple myeloma
  • 0 views
  • 19 Feb, 2024
  • 1 location